Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Whole genome sequencing of breast cancer

    Research output: Contribution to journalReviewResearchpeer-review

  2. Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Subtypes in BRCA-mutated breast cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Signe Borgquist
  • Anita Giobbie-Hurder
  • Thomas P Ahern
  • Judy E Garber
  • Marco Colleoni
  • István Láng
  • Marc Debled
  • Bent Ejlertsen
  • Roger von Moos
  • Ian Smith
  • Alan S Coates
  • Aron Goldhirsch
  • Manuela Rabaglio
  • Karen N Price
  • Richard D Gelber
  • Meredith M Regan
  • Beat Thürlimann
View graph of relations

Purpose Cholesterol-lowering medication (CLM) has been reported to have a role in preventing breast cancer recurrence. CLM may attenuate signaling through the estrogen receptor by reducing levels of the estrogenic cholesterol metabolite 27-hydroxycholesterol. The impact of endocrine treatment on cholesterol levels and hypercholesterolemia per se may counteract the intended effect of aromatase inhibitors. Patients and Methods The Breast International Group (BIG) conducted a randomized, phase III, double-blind trial, BIG 1-98, which enrolled 8,010 postmenopausal women with early-stage, hormone receptor-positive invasive breast cancer from 1998 to 2003. Systemic levels of total cholesterol and use of CLM were measured at study entry and every 6 months up to 5.5 years. Cumulative incidence functions were used to describe the initiation of CLM in the presence of competing risks. Marginal structural Cox proportional hazards modeling investigated the relationships between initiation of CLM during endocrine therapy and outcome. Three time-to-event end points were considered: disease-free-survival, breast cancer-free interval, and distant recurrence-free interval. Results Cholesterol levels were reduced during tamoxifen therapy. Of 789 patients who initiated CLM during endocrine therapy, the majority came from the letrozole monotherapy arm (n = 318), followed by sequential tamoxifen-letrozole (n = 189), letrozole-tamoxifen (n = 176), and tamoxifen monotherapy (n = 106). Initiation of CLM during endocrine therapy was related to improved disease-free-survival (hazard ratio [HR], 0.79; 95% CI, 0.66 to 0.95; P = .01), breast cancer-free interval (HR, 0.76; 95% CI, 0.60 to 0.97; P = .02), and distant recurrence-free interval (HR, 0.74; 95% CI, 0.56 to 0.97; P = .03). Conclusion Cholesterol-lowering medication during adjuvant endocrine therapy may have a role in preventing breast cancer recurrence in hormone receptor-positive early-stage breast cancer. We recommend that these observational results be addressed in prospective randomized trials.

Original languageEnglish
JournalJournal of clinical oncology : official journal of the American Society of Clinical Oncology
Volume35
Issue number11
Pages (from-to)1179-1188
Number of pages10
ISSN0732-183X
DOIs
Publication statusPublished - 10 Apr 2017

    Research areas

  • Aged, Anticholesteremic Agents, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Chemotherapy, Adjuvant, Cholesterol, Disease-Free Survival, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypercholesterolemia, Mastectomy, Segmental, Middle Aged, Neoplasm Recurrence, Local, Nitriles, Proportional Hazards Models, Radiotherapy, Adjuvant, Receptors, Estrogen, Receptors, Progesterone, Tamoxifen, Triazoles, Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial

ID: 52152400